Our homozygous A549GFPKRAS NSCLC cell line, generated using CRISPR/Cas9, has allowed us not only to assess localization of endogenously driven GFP-K-RAS protein, but its mobility shift has allowed us to test the utility of panRAS and K-RAS antibodies in detecting K-RAS by western blotting. This evidence concerns the gene KRAS and non-small cell lung carcinoma.